In fact, elucidation of the key mutations that drive melanoma progression has resulted in targeted therapies using small-molecule inhibitors of B-RAF and MEK either alone or in combination and has made significant progress in the treatment of melanoma (20, 27). This evidence concerns the gene MAP2K7 and melanoma.